Medical AI Investors Are Flocking to Hong Kong to Recruit PhDs
Summary
Hong Kong universities are drawing a growing wave of mainland investors seeking medical AI founders and technologies. The article highlights several 2026 projects: BrainCo Technology, an invasive brain-computer interface company, raised more than US$10 million in angel funding; Angxin Biology is using an AI drug-discovery platform in a cooperation with Dong’e Ejiao; and Ruoning Technology is applying AI large models and smart hardware to home management for chronic and mental illnesses. The investment rush follows a broader rise in Hong Kong university entrepreneurship. In the first half of 2026, founders linked to the Hong Kong University of Science and Technology reportedly led 25 financings across 19 companies worth more than RMB8.4 billion, while Chinese University of Hong Kong-linked founders recorded 15 companies and more than RMB1.5 billion. Embodied intelligence accounted for more than 70% of the cited financing total, but medical AI projects are gaining momentum. The article attributes the change to university commercialization systems, including HKUST incubation and funding programs, HKU technology transfer and challenge initiatives, and InnoHK research clusters. It also cites a HK$150 million FutureTech Stars fund established by HKU and Sinovation-linked capital, as well as a government plan to inject HK$1.5 billion into industry-academia research commercialization. Earlier Hong Kong-founded companies often placed their headquarters in Shenzhen because local healthcare infrastructure and early-stage risk capital were limited. Examples include AI diagnostics company Weimai Medical, surgical-robotics developer MicroPort MedBot-related company Kangnuos tendon, and liquid-biopsy company Jingzhun Medical, all of which connected Hong Kong research with mainland commercialization or manufacturing. In 2026, HKIC, mainland state-backed funds and industrial investors began entering Hong Kong projects more directly. The article says lower valuations, government-backed screening and the short distance between Hong Kong research and Shenzhen manufacturing are reducing commercialization risk. It presents this as an extension of a “Hong Kong R&D, mainland manufacturing” division of labor into medical AI, while leaving open whether the emerging ecosystem can produce durable medical AI businesses.